### India

**Population 2018** 1 353 million

<table>
<thead>
<tr>
<th>Estimates of TB burden, 2018</th>
<th>Number (thousands)</th>
<th>Rate (per 100,000 population)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total TB incidence</td>
<td>2 690 (1 840–3 700)</td>
<td>199 (136–273)</td>
</tr>
<tr>
<td>HIV-positive TB incidence</td>
<td>92 (63–126)</td>
<td>6.8 (4.6–9.3)</td>
</tr>
<tr>
<td>MDR/RR-TB incidence</td>
<td>130 (77–198)</td>
<td>9.6 (5.7–15)</td>
</tr>
<tr>
<td>HIV-negative TB mortality</td>
<td>440 (410–470)</td>
<td>32 (30–35)</td>
</tr>
<tr>
<td>HIV-positive TB mortality</td>
<td>8.7 (5.7–15)</td>
<td>0.72 (0.42–1.1)</td>
</tr>
</tbody>
</table>

**Estimated proportion of TB cases with MDR/RR-TB, 2018**

- % tested with rapid diagnostics at time of diagnosis: 50%
- % with known HIV status: 72%
- % pulmonary: 82%
- % bacteriologically confirmed: 57%
- % children aged 0–14 years: 6%
- % women: 34%
- % men: 60%

**TB case notifications, 2018**

- Total new and relapse: 1 994 000
- % tested with rapid diagnostics at time of diagnosis: 50%
- % with known HIV status: 72%
- % pulmonary: 82%
- % bacteriologically confirmed: 57%
- % children aged 0–14 years: 6%
- % women: 34%
- % men: 60%

**Universal health coverage and social protection**

- TB treatment coverage (notified/estimated incidence), 2018: 74% (54–110)
- TB patients facing catastrophic total costs: 17% (12–24)

**TB case fatality ratio (estimated mortality/estimated incidence), 2018**

- HIV-positive TB mortality: 9.7 (5.7–15) / 0.72 (0.42–1.1)

**Drug-resistant TB care, 2018**

- % of bacteriologically confirmed TB cases tested for rifampicin resistance: 46%
  - New cases: 46%
  - Previously treated cases: 91%

**Laboratory-confirmed cases**

- MDR/RR-TB: 58 347
- XDR-TB: 3 400

**Patients started on treatment**

- MDR/RR-TB: 46 569
- XDR-TB: 2 724

**MDR/RR-TB cases tested for resistance to second-line drugs**

- 38 236

**TB treatment coverage and social protection**

- TB/HIV care in new and relapse TB patients, 2018: 49 047
  - on antiretroviral therapy: 90%

**TB preventive treatment, 2018**

- % of HIV-positive people (newly enrolled in care) on preventive treatment: 17%
- % of children (aged < 5) household contacts of bacteriologically-confirmed TB cases on preventive treatment: 26% (24–28)

**Total TB budget (US$ millions)**

- 2015: 583
- 2016: 583
- 2017: 583
- 2018: 583
- 2019: 583

**TB financing, 2019**

- National TB budget (US$ millions): 583

**Funding source:** 77% domestic, 23% international, 0% unfunded

---

*Ranges represent uncertainty intervals

MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin

* Calculated for pulmonary cases only

Includes cases with unknown previous TB treatment history

** Includes patients diagnosed before 2018 and patients who were not laboratory-confirmed

---

Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.

Generated: 2020-04-11